# A Multicenter Assessment of ALD403 in Frequent Episodic Migraine

> **NCT02559895** · PHASE3 · COMPLETED · sponsor: **Alder Biopharmaceuticals, Inc.** · enrollment: 898 (actual)

## Conditions studied

- Migraine Disorders

## Interventions

- **DRUG:** ALD403
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02559895
- **Lead sponsor:** Alder Biopharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2017-02
- **Final completion:** 2017-12
- **Target enrollment:** 898 (ACTUAL)
- **Last updated:** 2020-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02559895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02559895, "A Multicenter Assessment of ALD403 in Frequent Episodic Migraine". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02559895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*